EP2970351 - RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS [Right-click to bookmark this link] | |||
Former [2016/03] | RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | ||
[2017/15] | Status | No opposition filed within time limit Status updated on 20.07.2018 Database last updated on 02.09.2024 | |
Former | The patent has been granted Status updated on 11.08.2017 | ||
Former | Grant of patent is intended Status updated on 23.03.2017 | ||
Former | Examination is in progress Status updated on 24.01.2017 | Most recent event Tooltip | 17.07.2020 | Lapse of the patent in a contracting state New state(s): AL | published on 19.08.2020 [2020/34] | Applicant(s) | For all designated states Translate Bio, Inc. 200 Sidney Street, Suite 310 Cambridge, MA 02139 / US | [2017/35] |
Former [2016/47] | For all designated states Shire Human Genetic Therapies, Inc. 300 Shire Way Lexington MA 02421 / US | ||
Former [2016/03] | For all designated states Shire Human Genetic Therapies, Inc. 300 Shire Way Lexington, MA 02421 / US | Inventor(s) | 01 /
DEROSA, Frank c/o SHIRE HUMAN GENETIC THERAPIES INC. 300 Shire Way Lexington, Massachusetts 02421 / US | 02 /
HEARTLEIN, Michael c/o SHIRE HUMAN GENETIC THERAPIES INC. 300 Shire Way Lexington, Massachusetts 02421 / US | [2016/03] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2016/03] | Application number, filing date | 14721635.2 | 14.03.2014 | [2016/03] | WO2014US27422 | Priority number, date | US201361785098P | 14.03.2013 Original published format: US 201361785098 P | [2016/03] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014152513 | Date: | 25.09.2014 | Language: | EN | [2014/39] | Type: | A1 Application with search report | No.: | EP2970351 | Date: | 20.01.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.09.2014 takes the place of the publication of the European patent application. | [2016/03] | Type: | B1 Patent specification | No.: | EP2970351 | Date: | 13.09.2017 | Language: | EN | [2017/37] | Search report(s) | International search report - published on: | EP | 25.09.2014 | Classification | IPC: | C12N15/67 | [2017/16] | CPC: |
A61P43/00 (EP);
C07H21/02 (US);
C12N15/67 (EP,US);
A61K9/1271 (US);
A61K9/1272 (US);
C12N2310/3515 (US)
|
Former IPC [2017/15] | C12N15/11, C12N15/67 | ||
Former IPC [2016/03] | C07H5/10, C12N15/11 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/03] | Extension states | BA | 07.09.2015 | ME | 07.09.2015 | Title | German: | RIBONUKLEINSÄUREN MIT 4'-THIO-MODIFIZIERTEN NUKLEOTIDEN UND ZUGEHÖRIGE VERFAHREN | [2016/03] | English: | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | [2017/15] | French: | ACIDES RIBONUCLÉIQUES AYANT DES NUCLÉOTIDES 4'-THIO-MODIFIÉS ET PROCÉDÉS ASSOCIÉS | [2016/03] |
Former [2016/03] | RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS | Entry into regional phase | 07.09.2015 | National basic fee paid | 07.09.2015 | Designation fee(s) paid | 07.09.2015 | Examination fee paid | Examination procedure | 07.09.2015 | Examination requested [2016/03] | 27.04.2016 | Amendment by applicant (claims and/or description) | 13.09.2016 | Despatch of a communication from the examining division (Time limit: M04) | 23.01.2017 | Reply to a communication from the examining division | 24.03.2017 | Communication of intention to grant the patent | 03.08.2017 | Fee for grant paid | 03.08.2017 | Fee for publishing/printing paid | 03.08.2017 | Receipt of the translation of the claim(s) | Divisional application(s) | EP17189627.7 / EP3301102 | EP20169380.1 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 13.09.2016 | Opposition(s) | 14.06.2018 | No opposition filed within time limit [2018/34] | Fees paid | Renewal fee | 31.03.2016 | Renewal fee patent year 03 | 27.03.2017 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 14.03.2014 | AL | 13.09.2017 | AT | 13.09.2017 | CY | 13.09.2017 | CZ | 13.09.2017 | DK | 13.09.2017 | EE | 13.09.2017 | FI | 13.09.2017 | HR | 13.09.2017 | LT | 13.09.2017 | LV | 13.09.2017 | MC | 13.09.2017 | MK | 13.09.2017 | NL | 13.09.2017 | PL | 13.09.2017 | PT | 13.09.2017 | RO | 13.09.2017 | RS | 13.09.2017 | SE | 13.09.2017 | SI | 13.09.2017 | SK | 13.09.2017 | SM | 13.09.2017 | TR | 13.09.2017 | BG | 13.12.2017 | NO | 13.12.2017 | GR | 14.12.2017 | IS | 13.01.2018 | IE | 14.03.2018 | LU | 14.03.2018 | MT | 14.03.2018 | BE | 31.03.2018 | CH | 31.03.2018 | LI | 31.03.2018 | [2020/34] |
Former [2020/31] | HU | 14.03.2014 | |
AT | 13.09.2017 | ||
CY | 13.09.2017 | ||
CZ | 13.09.2017 | ||
DK | 13.09.2017 | ||
EE | 13.09.2017 | ||
FI | 13.09.2017 | ||
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
MC | 13.09.2017 | ||
MK | 13.09.2017 | ||
NL | 13.09.2017 | ||
PL | 13.09.2017 | ||
PT | 13.09.2017 | ||
RO | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
SI | 13.09.2017 | ||
SK | 13.09.2017 | ||
SM | 13.09.2017 | ||
TR | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
IS | 13.01.2018 | ||
IE | 14.03.2018 | ||
LU | 14.03.2018 | ||
MT | 14.03.2018 | ||
BE | 31.03.2018 | ||
CH | 31.03.2018 | ||
LI | 31.03.2018 | ||
Former [2020/30] | HU | 14.03.2014 | |
AT | 13.09.2017 | ||
CZ | 13.09.2017 | ||
DK | 13.09.2017 | ||
EE | 13.09.2017 | ||
FI | 13.09.2017 | ||
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
MC | 13.09.2017 | ||
NL | 13.09.2017 | ||
PL | 13.09.2017 | ||
PT | 13.09.2017 | ||
RO | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
SI | 13.09.2017 | ||
SK | 13.09.2017 | ||
SM | 13.09.2017 | ||
TR | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
IS | 13.01.2018 | ||
IE | 14.03.2018 | ||
LU | 14.03.2018 | ||
MT | 14.03.2018 | ||
BE | 31.03.2018 | ||
CH | 31.03.2018 | ||
LI | 31.03.2018 | ||
Former [2020/28] | AT | 13.09.2017 | |
CZ | 13.09.2017 | ||
DK | 13.09.2017 | ||
EE | 13.09.2017 | ||
FI | 13.09.2017 | ||
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
MC | 13.09.2017 | ||
NL | 13.09.2017 | ||
PL | 13.09.2017 | ||
PT | 13.09.2017 | ||
RO | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
SI | 13.09.2017 | ||
SK | 13.09.2017 | ||
SM | 13.09.2017 | ||
TR | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
IS | 13.01.2018 | ||
IE | 14.03.2018 | ||
LU | 14.03.2018 | ||
MT | 14.03.2018 | ||
BE | 31.03.2018 | ||
CH | 31.03.2018 | ||
LI | 31.03.2018 | ||
Former [2020/16] | AT | 13.09.2017 | |
CZ | 13.09.2017 | ||
DK | 13.09.2017 | ||
EE | 13.09.2017 | ||
FI | 13.09.2017 | ||
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
MC | 13.09.2017 | ||
NL | 13.09.2017 | ||
PL | 13.09.2017 | ||
RO | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
SI | 13.09.2017 | ||
SK | 13.09.2017 | ||
SM | 13.09.2017 | ||
TR | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
IS | 13.01.2018 | ||
IE | 14.03.2018 | ||
LU | 14.03.2018 | ||
MT | 14.03.2018 | ||
BE | 31.03.2018 | ||
CH | 31.03.2018 | ||
LI | 31.03.2018 | ||
Former [2020/08] | AT | 13.09.2017 | |
CZ | 13.09.2017 | ||
DK | 13.09.2017 | ||
EE | 13.09.2017 | ||
FI | 13.09.2017 | ||
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
MC | 13.09.2017 | ||
NL | 13.09.2017 | ||
PL | 13.09.2017 | ||
RO | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
SI | 13.09.2017 | ||
SK | 13.09.2017 | ||
SM | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
IS | 13.01.2018 | ||
IE | 14.03.2018 | ||
LU | 14.03.2018 | ||
MT | 14.03.2018 | ||
BE | 31.03.2018 | ||
CH | 31.03.2018 | ||
LI | 31.03.2018 | ||
Former [2019/12] | AT | 13.09.2017 | |
CZ | 13.09.2017 | ||
DK | 13.09.2017 | ||
EE | 13.09.2017 | ||
FI | 13.09.2017 | ||
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
MC | 13.09.2017 | ||
NL | 13.09.2017 | ||
PL | 13.09.2017 | ||
RO | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
SI | 13.09.2017 | ||
SK | 13.09.2017 | ||
SM | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
IS | 13.01.2018 | ||
IE | 14.03.2018 | ||
LU | 14.03.2018 | ||
BE | 31.03.2018 | ||
CH | 31.03.2018 | ||
LI | 31.03.2018 | ||
Former [2019/09] | AT | 13.09.2017 | |
CZ | 13.09.2017 | ||
DK | 13.09.2017 | ||
EE | 13.09.2017 | ||
FI | 13.09.2017 | ||
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
MC | 13.09.2017 | ||
NL | 13.09.2017 | ||
PL | 13.09.2017 | ||
RO | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
SI | 13.09.2017 | ||
SK | 13.09.2017 | ||
SM | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
IS | 13.01.2018 | ||
IE | 14.03.2018 | ||
LU | 14.03.2018 | ||
Former [2019/04] | AT | 13.09.2017 | |
CZ | 13.09.2017 | ||
DK | 13.09.2017 | ||
EE | 13.09.2017 | ||
FI | 13.09.2017 | ||
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
MC | 13.09.2017 | ||
NL | 13.09.2017 | ||
PL | 13.09.2017 | ||
RO | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
SI | 13.09.2017 | ||
SK | 13.09.2017 | ||
SM | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
IS | 13.01.2018 | ||
LU | 14.03.2018 | ||
Former [2018/52] | AT | 13.09.2017 | |
CZ | 13.09.2017 | ||
DK | 13.09.2017 | ||
EE | 13.09.2017 | ||
FI | 13.09.2017 | ||
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
MC | 13.09.2017 | ||
NL | 13.09.2017 | ||
PL | 13.09.2017 | ||
RO | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
SI | 13.09.2017 | ||
SK | 13.09.2017 | ||
SM | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
IS | 13.01.2018 | ||
Former [2018/35] | AT | 13.09.2017 | |
CZ | 13.09.2017 | ||
DK | 13.09.2017 | ||
EE | 13.09.2017 | ||
FI | 13.09.2017 | ||
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
NL | 13.09.2017 | ||
PL | 13.09.2017 | ||
RO | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
SK | 13.09.2017 | ||
SM | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
IS | 13.01.2018 | ||
Former [2018/24] | AT | 13.09.2017 | |
CZ | 13.09.2017 | ||
EE | 13.09.2017 | ||
FI | 13.09.2017 | ||
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
NL | 13.09.2017 | ||
PL | 13.09.2017 | ||
RO | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
SK | 13.09.2017 | ||
SM | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
IS | 13.01.2018 | ||
Former [2018/23] | AT | 13.09.2017 | |
CZ | 13.09.2017 | ||
EE | 13.09.2017 | ||
FI | 13.09.2017 | ||
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
NL | 13.09.2017 | ||
PL | 13.09.2017 | ||
RO | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
SK | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
IS | 13.01.2018 | ||
Former [2018/21] | CZ | 13.09.2017 | |
FI | 13.09.2017 | ||
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
NL | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
Former [2018/15] | FI | 13.09.2017 | |
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
NL | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
Former [2018/12] | FI | 13.09.2017 | |
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
LV | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
Former [2018/11] | FI | 13.09.2017 | |
HR | 13.09.2017 | ||
LT | 13.09.2017 | ||
RS | 13.09.2017 | ||
SE | 13.09.2017 | ||
BG | 13.12.2017 | ||
NO | 13.12.2017 | ||
GR | 14.12.2017 | ||
Former [2018/09] | FI | 13.09.2017 | |
LT | 13.09.2017 | ||
SE | 13.09.2017 | ||
NO | 13.12.2017 | ||
Former [2018/08] | FI | 13.09.2017 | |
LT | 13.09.2017 | ||
NO | 13.12.2017 | ||
Former [2018/07] | LT | 13.09.2017 | |
NO | 13.12.2017 | Cited in | International search | [AD] - MICHAEL S D KORMANN ET AL, "Expression of therapeutic proteins after delivery of chemically modified mRNA in mice", NATURE BIOTECHNOLOGY, (20110201), vol. 29, no. 2, doi:10.1038/nbt.1733, ISSN 1087-0156, pages 154 - 157, XP055040839 [AD] 1-29 * the whole document * DOI: http://dx.doi.org/10.1038/nbt.1733 | [A] - B. R. ANDERSON ET AL, "Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L", NUCLEIC ACIDS RESEARCH, (20111101), vol. 39, no. 21, doi:10.1093/nar/gkr586, ISSN 0305-1048, pages 9329 - 9338, XP055126203 [A] 1-29 * the whole document * DOI: http://dx.doi.org/10.1093/nar/gkr586 | [AD] - KARIKÓ KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 16, no. 11, doi:10.1038/MT.2008.200, ISSN 1525-0024, (20081101), pages 1833 - 1840, (20080916), XP002598556 [AD] 1-29 * the whole document * DOI: http://dx.doi.org/10.1038/mt.2008.200 | [AD] - DANDE PRASAD ET AL, "Improving RNA interference in mammalian cells by 4'-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2'-O-alkyl modifications", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 49, no. 5, doi:10.1021/JM050822C, ISSN 0022-2623, (20060309), pages 1624 - 1634, (20060208), XP002611368 [AD] 1-29 * abstract * DOI: http://dx.doi.org/10.1021/JM050822C | [A] - JONES G D ET AL, "DUPLEX- AND TRIPLEX-FORMING PROPERTIES OF 4'-THIO-MODIFIED OLIGODEOXYNUCLEOTIDES", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (19970520), vol. 7, no. 10, doi:10.1016/S0960-894X(97)00208-4, ISSN 0960-894X, pages 1275 - 1278, XP004136316 [A] 1-29 * the whole document * DOI: http://dx.doi.org/10.1016/S0960-894X(97)00208-4 | [A] - A HUTTENHOFER AND H.F. NOLLER, "Footprinting mRNA-ribosome complexes with chemical probes", THE EMBO JOURNAL, (19940101), vol. 13, no. 16, pages 3892 - 3901, XP055131438 [A] 1-29 * the whole document * | [A] - DEMESHKINA N ET AL, "Interactions of the ribosome with mRNA and tRNA", CURRENT OPINION IN STRUCTURAL BIOLOGY, ELSEVIER LTD, GB, vol. 20, no. 3, doi:10.1016/J.SBI.2010.03.002, ISSN 0959-440X, (20100601), pages 325 - 332, (20100412), XP027067342 [A] 1-29 * the whole document * DOI: http://dx.doi.org/10.1016/j.sbi.2010.03.002 | by applicant | WO2010053572 | WO2011006810 | WO2011068810 | WO2012170930 | WO2012170889 | - YAMAMOTO, A. ET AL., EUR. J. PHARM., (2009), vol. 71, pages 484 - 489 | - DEBUS, H. ET AL., J. CONTROL REL., (2010), vol. 148, pages 334 - 343 | - M. KORMANN ET AL., NATURE BIOTECH., (2011), vol. 29, pages 154 - 159 | - K. KARIKO, MOLECULAR THERAPY, (2008), vol. 16, no. 11, pages 1833 - 1840 | - S. HOSHIKA ET AL., NUC. AC. RES. SUPP., (2003), vol. 3, pages 209 - 210 | - M. TAKAHASHI, M. ET AL., NUC. AC. RES., (2009), vol. 37, pages 1353 - 1362 | - DANDE ET AL., J. MED. CHEM., (2006), vol. 49, pages 1624 - 1634 | - HOSHIKA ET AL., NUC. AC. RES., (2004), vol. 32, pages 3815 - 3825 | - KATO ET AL., NUC. AC. RES., (2005), vol. 33, pages 2942 - 2951 | - MINAKAWA ET AL., BIOORG. MED. CHEM., (2008), vol. 16, pages 9450 - 9456 | - HUM. GENE THER., (2008), vol. 19, no. 9, pages 887 - 95 | - LASIC ET AL., TRENDS BIOTECHNOL., (1998), vol. 16, pages 307 - 321 | - DRUMMOND ET AL., PHARMACOL. REV., (1999), vol. 51, pages 691 - 743 | - HEYES ET AL., J. CONTR. REL., (2005), vol. 107, pages 276 - 287 | - SEMPLE ET AL., NATURE BIOTECH., (2010), vol. 28, pages 172 - 176 | - LOVE ET AL., PROC. NAT'L. ACAD. SCI., (2010), vol. 107, pages 1864 - 1869 | - FECHTER; BROWNLEE, J. GEN. VIROLOGY, (2005), vol. 86, pages 1239 - 1249 | - HEYES, J.; PALMER, L.; BREMNER, K.; MACLACHLAN, 1, "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J. CONTR. REL., (2005), vol. 107, doi:doi:10.1016/j.jconrel.2005.06.014, pages 276 - 287, XP008157522 DOI: http://dx.doi.org/10.1016/j.jconrel.2005.06.014 | - SEMPLE, S.C. ET AL., "Rational Design of Cationic Lipids for siRNA Delivery", NATURE BIOTECH., (2010), vol. 28, doi:doi:10.1038/NBT.1602, pages 172 - 176, XP002633693 DOI: http://dx.doi.org/10.1038/NBT.1602 | - LOVE, K.T. ET AL., "Lipid-like materials for low-dose in vivo gene silencing", PNAS, (2010), vol. 107, doi:doi:10.1073/pnas.0910603106, pages 1864 - 1869, XP055077922 DOI: http://dx.doi.org/10.1073/pnas.0910603106 | - FECHTER, P.; BROWNLEE, G.G., "Recognition of mRNA cap structures by viral and cellular proteins", J. GEN. VIROLOGY, (2005), vol. 86, doi:doi:10.1099/VIR.0.80755-0, pages 1239 - 1249, XP002516933 DOI: http://dx.doi.org/10.1099/VIR.0.80755-0 | - BOGACHEV, V.S., "Synthesis of deoxynucleoside 5'-triphosphates using trifluoroacetic anhydride as activation reagent", RUSS. J. BIOORG. CHEM., (1996), vol. 22, pages 599 - 604 |